The Joslin DRC

Since its founding in 1898, the mission of the Joslin Diabetes Center has been to improve the lives of patients with diabetes through research, clinical care, and education to find new treatments, improve care and prevent disease in those at risk. Over the past 35 years, this research at Joslin has been supported by NIH/NIDDK through a Diabetes Research Center (DRC) Program Grant led by George L. King, MD.
 

Mission of the DRC at Joslin

  • Create an environment that supports world-class investigation in diabetes and metabolism.
  • Sustain and strengthen the diabetes research infrastructure through core laboratories that provide outstanding expertise and cutting-edge technologies.
  • Catalyze new diabetes research and multidisciplinary collaborations that transform the field of diabetes research through support of early-stage research (Pilot and Feasibility Program) and a comprehensive program of seminars and symposia (Enrichment Program).
  • Translate new knowledge to improved care and prevention.

Explore Our DRC Cores

When it comes to diabetes, Joslin is a research powerhouse. Our NIH/NIDDK funded cores provide critical services to keep our research initiatives moving forward.

Animal Physiology

The purpose of the Animal Physiology Core is to provide technically advanced physiological evaluation of metabolism in diabetes, obesity, and the associated complications in rodents for Joslin Diabetes Research Center investigators and outside users.

Clinical Translational Research Core

The Joslin Clinical Translational Research Center offers a safe, comfortable, and effective environment to conduct outpatient clinical research studies.

Flow Cytometry

The Joslin Flow Cytometry Core provides reliable and affordable cell sorting and flow cytometry services to its users so that they can isolate, analyze, and study cells that increase our understanding of diabetes and its complications, and ultimately, develop treatments and cures for these diseases.

Genome Editing Core

The Genome Editing Core (GEC) provides investigators with resources to manipulate the genome of human cell lines and laboratory mice with the aim of studying genetics underlying diabetes and its complications.

Molecular Phenotyping & Genotyping

The objective of the Molecular Phenotyping and Genotyping Core is to support Joslin and external investigators in the study of molecular mechanisms of disease by providing equipment, expertise, and services in molecular phenotyping.

Research Seminars

The Diabetes and Metabolism Research Seminars are held on Thursdays at Noon in the Samuelian Lecture Hall.

Research News

We’re constantly pushing forward toward the next great discovery.

Newly discovered proteins provide protection against progression of kidney disease in diabetes

Elevated levels of three specific circulating proteins are associated with protection against kidney failure in diabetes, according to research from the Joslin Diabetes Center that will be published...
Read more on Newly discovered proteins provide protection against progression of kidney disease in diabetes

Pain receptors linked to the generation of energy-burning fat cells: implications for obesity therapy

Vascular smooth muscle-derived Trpv1+ progenitors have found to be a source of cold-induced "brown fat" BOSTON – April 12, 2021) – A new source of energy expending brown fat cells has been uncovered...
Read more on Pain receptors linked to the generation of energy-burning fat cells: implications for obesity therapy

Ancient gut microbiomes may offer clues to modern diseases

Genomic analysis of human samples from dry caves shows stark differences with modern industrialized bacterial populations. BOSTON – ( May 12, 2021) – Scientists are rapidly gathering evidence that...
Read more on Ancient gut microbiomes may offer clues to modern diseases

The DRC offers researchers specialized cutting-edge technology assistance as well as a network of colleagues from across the medical and scientific community. Joslin is proud to have been selected as one of only 16 NIDDK-funded DRCs across the country.



George L. King, M.D.
Chief Scientific Officer

Read a message from George L. King, M.D., Chief Scientific Officer, on what sets our diabetes research apart from other institutions.